Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867317 · ClinicalTrials.gov registry record · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
A Phase 3 study of Mild Traumatic Brain Injury and Adult Growth Hormone Deficiency, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 172
- Enrollment target
- 4
- Study locations
NCT04867317 is a Phase 3 study of Mild Traumatic Brain Injury and Adult Growth Hormone Deficiency that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 172 participants, below the 217-participant average among 43 other Mild Traumatic Brain Injury trials with a reported enrollment target (21% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04867317, a Phase 3 study of Mild Traumatic Brain Injury and Adult Growth Hormone Deficiency, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 172 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Somatropin
Study Locations (4)
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Minnesota
- Minneapolis VA Health Care System, Minneapolis, MN - Minneapolis
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Washington
- VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04867317
The ClinicalTrials.gov registry entry for NCT04867317 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 43 other Mild Traumatic Brain Injury trials with a reported enrollment target (21% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04867317 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT04867317 about?
NCT04867317 is a clinical study titled "Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)". The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
What is the current status of trial NCT04867317?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2025-01-13. Estimated completion is 2028-03-01.
What conditions does trial NCT04867317 study?
This clinical trial studies the following conditions: Mild Traumatic Brain Injury, Adult Growth Hormone Deficiency.
What interventions are being tested in trial NCT04867317?
The interventions under investigation include: Placebo (OTHER), Somatropin (DRUG).
Who is sponsoring clinical trial NCT04867317?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04867317 being conducted?
This trial has 4 study locations across Georgia, Minnesota, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)
RECRUITING · Phase 3
-
Concussion Recovery and Support Program
RECRUITING · NA
-
Vestibular Rehabilitation App for Adults With Dizziness Related to mTBI
RECRUITING · NA
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Risk Stratification in Children With Concussion
RECRUITING
-
Combined Neuromodulation and Cognitive Training for Post-mTBI Depression
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.